# US 11,026,940 B2 · Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,026,940 B2
- Document ID: US11026940B2
- Status: Granted
- Kind: B2
- Application number: 15/723,687
- Filed: 2017-10-03
- Published: 2018-06-07
- Granted: 2021-06-08
- Earliest claimed: 2013-03-15
- Assignees: Ampio Pharmaceuticals, Inc.
- Applicants: Ampio Pharmaceuticals, Inc.
- Inventors: David Bar-Or; Greg Thomas
- Web page: https://patentgrep.com/patent/US11026940B2

## CPC

- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0663: {Bone marrow mesenchymal stem cells (BM-MSC)}
- A61K 35/32: Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
- C12N 2501/999: Small molecules not provided for elsewhere
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides compositions that increase the mobilization, homing, expansion, and/or differentiation of stem cells and methods of using the same for the treatment of mammals.

## Claims

### Claim 1

A composition, comprising:
a low molecular weight fraction of a human serum albumin pharmaceutical composition comprising aspartyl-alanyl diketopiperazine (DA-DKP), N-acetyl tryptophan, and caprylate and/or caprylic acid, wherein:
albumin has been removed by filtration;
the molecular weight of the fraction is less than 5000;
the fraction comprises DA-DKP; and
a cell culture medium supplemented with said supplement is capable of supporting the expansion of stem cells.

### Claim 2 (depends on 1)

The composition of claim 1, further comprising stem cells in a serum-free media.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the low molecular weight fraction of the human serum albumin pharmaceutical composition is prepared by heating human serum albumin under conditions effective to cause the formation of DA-DKP.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the low molecular weight fraction of the human serum albumin pharmaceutical composition is prepared by contacting human serum albumin with an enzyme that cleaves the two N-terminal amino acids of human albumin under conditions effective to produce DA-DKP.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the DA-DKP is synthetic.

### Claim 6 (depends on 2)

The composition of claim 2, wherein the stem cells are selected from the group consisting of progenitor cells and mesenchymal stem cells.